<DOC>
	<DOC>NCT02363491</DOC>
	<brief_summary>The dose-confirming part of this study, comprising at least 10 patients is designed as a single center, prospective, single arm, open label in patients who have failed or are unresponsive to Azacitidine (AZA) or Decitabine (they may also have additionally failed an Erythropoiesis Stimulating Agent (ESA) followed by a dose expansion part with an additional 30 patients; the objective of the whole study being to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of intravenously infused multiple doses of OPN-305 in low and intermediate-1 risk myelodysplastic syndrome (Second line Lower risk MDS).</brief_summary>
	<brief_title>A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Written informed consent Age ≥ 18 years Diagnosis of MDS (de novo or secondary) by bone marrow biopsy based on the World Health Organization (WHO) classification Low and Intermediate1 risk categories MDS using the IPSS (International Prognostic Scoring System) Not responding or failed treatment on AZA or decitabine (note they are also eligible if additionally they have failed another ESA after at least 4 cycles) Responders who cease responding Never responded Red Blood cell transfusion dependent (defined as ≥ 2 RBC units required in the 8 weeks prior to starting in the study). Life expectancy ≥ 3 months ECOG performance status Grade 02 Serum bilirubin levels ≤2 x ULN Serum ALT and AST levels ≤2.5 x ULN Creatinine clearance &gt; 50 ml/min calculated by the CockcroftGault formula Negative urine βhuman chorionic gonadotropin (βHCG) pregnancy test for fertile women at screening and confirmed by serum pregnancy test in the 48 hours prior to OPN305 administration If sexually active female, patient must be/have one of the following: Postmenopausal defined as the absence of menses for at least one year (serum FSH ≥20IU/L can also be measured according to local practice), OR Surgically sterile defined as a bilateral tubal ligation at least 6 months prior to administration of study drug, bilateral oophorectomy, or complete hysterectomy, OR Using an effective means of contraception that is planned to continue for the duration of treatment and for a further 3 months. If sexually active male, patient must: Agree to use an effective means of contraception (per sitespecific guidelines) that is planned to continue until 6 months after the last dose of OPN305. Agree not to donate sperm until 6 months after the last dose of OPN305 Diagnosis of MDS by bone marrow biopsy of Intermediate2 and High risk category MDS based on the WHO classification using the IPSS (International Prognostic Scoring System) Patients with 5q del MDS unless failed on Revlimid (lenalidomide) Prior history of acute leukemia or AML Unable/unwilling to undergo bone marrow sampling Prior history of bone marrow transplantation Prior malignancy (other than noninvasive malignancy including in situ cervical cancer, Bowen's disease or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for 3 years before randomization Active viral or bacterial infections: this includes any infections that are being actively treated even if the signs and symptoms appear to have resolved. Courses of antibiotics or antiviral treatment should be completed before the patient is enrolled Unstable angina, congestive heart failure [NYHA (New York Heart Association) &gt;class II], uncontrolled hypertension [diastolic &gt; 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction, uncontrolled diabetes mellitus Clinical Evidence of CNS disease Less than 4 weeks since any therapy for MDS Prior history of anaphylaxis with this product type History or presence of a medical condition or disease or substance abuse that in the investigator's assessment would place the patient at an unacceptable risk for study participation Lactating or pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>